Guselkumab Improves Disease Activity and Retention in Psoriatic Arthritis
Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.
Guselkumab, an interleukin-23 inhibitor, was associated with significant improvements in disease activity and a high treatment retention rate among patients with psoriatic arthritis (PsA), according to study findings published in ARP Rheumatology.
Researchers conducted a retrospective multicenter cohort study to evaluate the 12-month efficacy, safety, and persistence of guselkumab among adults with PsA who received care across 3 medical centers in Italy.
- The study included 70 patients with PsA who initiated guselkumab due to arthritis activity and had at least 12 months of follow-up.
- At baseline, patients were aged a median of 59 years and 44% were women.
Author's summary: Guselkumab improves PsA disease activity.